NCT04419519View on ClinicalTrials.gov

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 13, 2020

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Interventions
DRUG

Venetoclax monotherapy

Venetoclax monotherapy

DRUG

Venetoclax with anti CD20 monoclonal antibody

Venetoclax with anti CD20 monoclonal antibody

Trial Locations (9)

10032

ACTIVE_NOT_RECRUITING

Columbia University, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All protocol activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All protocol activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Commack (All protocol activities), Commack

98109

ACTIVE_NOT_RECRUITING

University of Washington, Seattle

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All protocol activities), Montvale

Sponsors

Collaborators (1)

Adaptive Biotechnologies
All Listed Sponsors
collaborator

Adaptive Biotechnologies

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER